Aripiprazole for Adolescents With Schizophrenia
About this title
Read the official source — NCT01149655This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Downy and 51 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 252
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, India, Malaysia, ...
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT01149655
- Official title
Show the full official title
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Downy, United States · Glendale, United States · Miami, United States
48 more locations
- Miami Springs, United States
- Atlanta, United States
- Bloomfield Hills, United States
- Chapel Hill, United States
- Bothell, United States
- Vijayawada, India
- Visakhapatnam, India
- Raipur, India
- Maninagar, Ahmedabad, India
- Chhatrapati Sambhajinagar, India
- Wardha, India
- Chennai, India
- Madurai, India
- Lucknow, India
- Varanasi, India
- Guntur, India
- Kuala Lumpur, Malaysia
- Ipoh, Malaysia
- Batu Caves, Malaysia
- Johor Bahru, Malaysia
- Dasmariñas, Philippines
- Bajada, Philippines
- Manila, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Cluj-Napoca, Romania
- Craiova, Romania
- Timișoara, Romania
- Bucharest, Romania
- Iași, Romania
- Arkhangelsk, Russia
- Kazan', Russia
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Novosibirsk, Russia
- Orenburg, Russia
- Petrozavodsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Tonnelnyi Township, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Kaohsiung County, Taiwan
- Taipei, Taiwan
- Taoyuan County, Taiwan
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
